FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

Danmei Yu,Zhou Lu,Ruyu Wang,Yusen Xiang,Hongtao Li,Jiani Lu,Lijun Zhang,Hongzhuan Chen,Weihua Li,Xin Luan,Lili Chen

DOI: https://doi.org/10.1016/j.bcp.2023.115570

IF: 6.1

2023-04-29

Biochemical Pharmacology

Abstract:Farnesoid X receptor (FXR, NR1H4) is generally considered as a tumor suppressor of colorectal and liver cancers. The interaction between FXR, bile acids (BAs) and gut microbiota is closely associated with an increased risk of colorectal and liver cancers. Increasing evidence shows that FXR agonists may be potential therapeutic agents for colorectal and liver cancers. However, FXR agonists alone do not produce the desired results due to the complicated pathogenesis and single therapeutic mechanism, which suggests that effective treatments will require a multimodal approach. Based on the principle of improving efficacy and reducing side effects, combination therapy is currently receiving considerable attention. In this review, colorectal and liver cancers are grouped together to discuss the effects of FXR agonists alone or in combination for combating the two cancers. We hope that this review will provide a theoretical basis for the clinical application of novel FXR agonists or combination with FXR agonists against colorectal and liver cancers.

pharmacology & pharmacy